A number of research firms have changed their ratings and price targets for Aerie Pharmaceuticals (NASDAQ: AERI):

  • 10/23/2017 – Aerie Pharmaceuticals is now covered by analysts at Guggenheim. They set a “buy” rating on the stock.
  • 10/16/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock. They wrote, “We expect an approval on or prior to the PDUFA date.””
  • 10/16/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $76.00 price target on the stock, up previously from $65.00.
  • 10/16/2017 – Aerie Pharmaceuticals had its “positive” rating reaffirmed by analysts at Canaccord Genuity. They now have a $73.00 price target on the stock, up previously from $65.00.
  • 10/11/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $62.00 price target on the stock.
  • 10/11/2017 – Aerie Pharmaceuticals was given a new $65.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 10/11/2017 – Aerie Pharmaceuticals was given a new $68.00 price target on by analysts at JMP Securities. They now have a “buy” rating on the stock.
  • 10/10/2017 – Aerie Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. A further delay will impact the growth prospects. A meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13 to review the NDA. A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Aerie’s shares performed worse than the industry in the last three months.”
  • 10/5/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 10/2/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock.
  • 9/22/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity.
  • 9/20/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock.
  • 9/17/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $65.00 price target on the stock.
  • 9/6/2017 – Aerie Pharmaceuticals is now covered by analysts at Mizuho. They set a “buy” rating and a $70.00 price target on the stock.
  • 8/28/2017 – Aerie Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Aerie had earlier withdrawn its NDA that was filed in September A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Moreover, Aerie’s shares have outperformed the industry in the year so far. The recent data on Roclatan is also positive. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa.”

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) opened at 63.30 on Tuesday. The firm has a 50-day moving average price of $56.90 and a 200-day moving average price of $51.75. The company’s market cap is $2.30 billion. Aerie Pharmaceuticals, Inc. has a 12-month low of $32.05 and a 12-month high of $66.10.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.02. On average, equities research analysts forecast that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.